Pressure BioSciences (PBIO) 10-Q2004 Q1 Quarterly report

Filed: 17 May 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: abandoning, addressed, advance, advisory, Agency, alleged, apparent, asserted, assumption, Avallone, bench, Blair, Bruce, category, cease, Chicago, claimed, commitment, committing, comply, comprised, concurrent, contemplated, contingent, customary, daughter, deadline, defective, delivery, depreciation, disability, discretion, disposition, disrupted, drawn, eleven, eligible, engineering, entirety, Environmental, EPA, European, exceed, extended, extension, failure, Family, feet, foregoing, founder, ft, gathering, Henson, historical, hold, iii, importing, Incremental, insurance, investigating, iv, jointly, landlord, lender, Letter, lived, LOI, LP, Manafort, MD, medical, member, Michael, million, minimal, minimum, month, occupancy, occupied, Oceanside, ordinary, owe, paragraph, partner, pay, penalty, predecessor, proforma, pronouncement, Protection, protein, purport, purported, quantify, range, readily, ready, recalled, receipt, referenced, rent, requested, resolution, respond, return, revolving, royalty, Sargeant, SBIR, seracare, shortly, Simultaneously, slower, smaller, space, sq, summary, table, temporarily, top, transfer, travel, unanticipated, unforeseen, unrelated, unused, user, vacant, vacating, version, vigorously, waste, wrote

Removed: achieved, acquire, acquiring, adversely, announcing, ARB, attempt, attempting, attract, audit, automatically, aware, BarocyclerTM, beneficial, beneficially, beneficiary, billable, biology, book, buildup, buyer, calling, cell, center, close, coercive, combination, combined, consolidate, consolidation, constituted, continue, controlling, created, CT, custom, declared, declined, deliverable, deter, discount, distribution, earlier, earning, effort, EITF, element, elimination, Emerging, equal, exchanged, exercisable, expire, FIN, foot, Force, guarantee, guarantor, guidance, holder, impacted, inception, Indirect, individual, initial, Initially, initiated, installation, insufficient, interpretation, introduction, Issue, issuing, lengthen, loaned, merger, molecular, multiple, mutual, original, overseeing, owner, Participating, permanent, permanently, person, personal, primary, promotion, prospective, purpose, raw, reached, receiving, redeem, redeemed, reevaluated, registered, reimbursable, renewable, repaid, repayment, replaced, rescission, reserve, response, restrictive, restructuring, resulting, retain, satisfied, sentence, serve, shipment, sublease, subscribed, support, takeover, Task, threshold, timeframe, trading, treatment, twenty, undertaken, unfair, unsolicited, variable, VIE, void, Wilson, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

In connection with the Quarterly Report on Form 10-Q of Boston Biomedica, Inc., a Massachusetts corporation (the “Company”) for the period ended March 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael N. Avallone, Vice President, Finance and Chief Financial Officer of Boston Biomedica, Inc., a Massachusetts corporation (the “Company”), do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:

(1) The Report of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 14, 2004		/s/ Michael N. Avallone
	Michael N. Avallone
	Vice President, Finance and Chief Financial Officer
	(Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to Boston Biomedica, Inc. and will be retained by Boston Biomedica, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.